Companies › BioRestorative Therapies
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BRTX-100 Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous | – | Phase 2 | Lumbar Disc Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04042844 | BRTX-100 | Phase 2 | Lumbar Disc Disease | Other | Dec 2026 |
Cash and short-term investments of $4m on 2026-03-31; operating cash outflow about $16m a year; runway about 3 months at that burn, to Jun 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Tego Science Ascendis Pharma Endocrinology Division Eirion Therapeutics Airway Therapeutics Inotrem
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.